RT Journal Article
T1 Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
A1 Behr, Jürgen
A1 Demedts, Maurits
A1 Buhl, Roland
A1 Costabel, Ulrich
A1 Dekhuijzen, Richard P N
A1 Jansen, Henk M
A1 MacNee, William
A1 Thomeer, Michiel
A1 Wallaert, Benoit
A1 Laurent, Francois
A1 Nicholson, Andrew G
A1 Verbeken, Eric K
A1 Verschakelen, Johny
A1 Flower, C D R
A1 Petruzzelli, Stefano
A1 De Vuyst, Paul
A1 van den Bosch, J M M
A1 Rodriguez-Becerra, Eulogio
A1 Lankhorst, Ida
A1 Sardina, Marco
A1 Boissard, Gabrielle
K1 Anciano
K1 Azatioprina
K1 Progresión de la efermedad
K1 Método doble ciego
K1 Quimioterapia combinada
K1 Europa (continente)
K1 Prueba de esfuerzo
K1 Femenino
K1 Humanos
K1 Pulmón
K1 Fibrosis pulmonar Idiopática
K1 Mediana edad
K1 Pacientes desistentes del Tratamiento
K1 Prednisona
K1 Fármacos del sistema respiratorio
K1 Índice de severidad de la enfermedad
K1 Resultado del tratamiento
K1 Capacidad vital
K1 Acetilcisteína
AB BACKGROUNDThe randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine, significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set.METHODSWe analysed effects of NAC on VC, DLco, a composite physiologic index (CPI), and mortality in the 155 study-patients.RESULTSIn trial completers the functional indices did not change significantly with NAC, whereas most indices deteriorated with placebo; in non-completers the majority of indices worsened but decline was generally less pronounced in most indices with NAC than with placebo. Most categorical analyses of VC, DLco and CPI also showed favourable changes with NAC. The effects of NAC on VC, DLco and CPI were significantly better if the baseline CPI was 50 points or lower.CONCLUSIONThis descriptive analysis confirms and extends the favourable effects of NAC on lung function in IPF and emphasizes the usefulness of VC, DLco, and the CPI for the evaluation of a therapeutic effect. Most importantly, less progressed disease as indicated by a CPI of 50 points or lower at baseline was more responsive to therapy in this study.
PB BIOMED CENTRAL LTD
SN 1465-9921
YR 2009
FD 2009-10-27
LK http://hdl.handle.net/10668/1657
UL http://hdl.handle.net/10668/1657
LA en
NO Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, et al. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir. Res. 2009; 10:101
NO Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Trial Registration: Registered at http://www.ClinicalTrials.gov; number NCT00639496.
DS RISalud
RD Apr 17, 2025